Intelligent hyaluronidase-responsive supramolecular nanoassemblies for programmable dual-drug delivery and NIR-II photothermal therapy of atherosclerosis.

ABSTRACT: The development of controllable nanoplatforms with disease-specific responsiveness and programmable therapeutic functions is vital for treating complex cardiovascular diseases such as atherosclerosis. Herein, we present an intelligent, next-generation nanoplatform (HALA@Ag₂S) that integrates enzyme-responsive dual-drug delivery with NIR-II imaging-guided photothermal therapy (PTT), enabling triple-stimuli synergy of enzyme, light, and multi-drug co-activation. This modular design enables stable nanoassemblies with high drug-loading capacity and selective disassembly in enzyme-rich plaque microenvironments, achieving controlled dual-drug release exceeding 80 % within 72 h. Importantly, the unique integration of dual pharmacotherapy and NIR-II PTT within a single platform enables

SUBMITTER: Liang H 

PROVIDER: S-EPMC12408412 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature